Overview

MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)

Status:
Completed
Trial end date:
2009-10-23
Target enrollment:
Participant gender:
Summary
A study to evaluate the efficacy and safety of MK0431A in comparison to a commonly used medication in patients with type 2 diabetes
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Metformin
Pioglitazone
Sitagliptin Phosphate